Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.

• ClinicalTrials.gov Identifier: NCT03564665
• Recruitment Status: Completed
• First Posted: June 21, 2018
• Last Update Posted: April 12, 2021
• Sponsor: Mayo Clinic
• Information provided by (Responsible Party): Dawn M. Mussallem, D.O., Mayo Clinic

Study Description

Brief Summary:

The goal of this study is to further evaluate the effect of magnesium on the symptoms of menopause, specifically vasomotor symptoms (VMS) in breast cancer patients and/or women at an elevated risk of breast cancer.

Condition or disease	Intervention/treatment	Phase
Hot Flashes	Dietary Supplement: 400mg Magnesium Glycinate BID; Other: Placebo	Not Applicable

Detailed Description:

Hot flashes are one of the most common symptoms that are experienced in women during perimenopause, menopause, and as a result of treatment of cancer such as breast cancer. Hot flashes, also known as vasomotor symptoms (VMS) may decrease a woman's quality of life due to discomfort, disruption of daily life, interruption of sleep, and worsening of depression. Previously, estrogen-based therapy was the primary treatment choice for VMS. However, in recent years, this has been considered less favorable due to the increased risk of breast cancer associated with estrogen-based therapy.

While medications such as certain antidepressants, gabapentin and clonidine are available as non-hormonal treatment options, they appear to be less effective in comparison to estrogen therapy with reported adverse effects.

Magnesium supplementation has been found to have very promising results in alleviating VMS in patients with a history of breast cancer. The goal of this study is to further investigate the effects of administering magnesium supplementation in reducing the effects of hot flashes in this targeted population. Our aim is to create a controlled trial using different dosages of magnesium glycinate in the management of hot flashes. Participants will be asked to complete surveys for data collection and analysis.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Randomized, Placebo Controlled, Single Blinded
• Masking: Single (Participant)
• Masking Description: Placebo
• Primary Purpose: Treatment
• Official Title: A Randomized, Placebo Controlled, Single Blinded Trial of 400mg of Magnesium Glycinate BID Investigating the Body's Structure/Function Role of Hot Flashes.
• Actual Study Start Date: July 24, 2018
• Actual Primary Completion Date: April 10, 2021
• Actual Study Completion Date: April 10, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: 400mg Magnesium Glycinate BID Arm; Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.	Dietary Supplement: 400mg Magnesium Glycinate BID; 400mg Magnesium Glycinate BID for 8 weeks.
Placebo Comparator: Control Arm; Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.	Other: Placebo; Placebo BID for 8 weeks.

Outcome Measures

Primary Outcome Measures :

1. Percent change in hot flash frequency [ Time Frame: 8 weeks. ]
   The primary endpoint of this study will be the percent change in hot flash frequency from baseline to week 8. A two independent sample z-test (assuming equal variances) or a Wilcoxon rank-sum test will be used for the analysis of this endpoint.

Secondary Outcome Measures :

1. Average change in hot flash frequency from baseline to week 8 [ Time Frame: 8 weeks ]
   The secondary analysis, we will also look at the average change in hot flash frequency from baseline to week 8 and compare these means using a two-sample t-test or a Wilcoxon rank-sum test. Adverse events (as captured using the NCI CTCAE version 4) will be compared between the two investigational arms using summary statistics. Frequencies of adverse events will be compared using chi-square tests or Fisher's exact tests. Change in QOL (as measured by the MDASI) from baseline to week 8 will be compared for each question between the investigational arms using two sample t-tests or Wilcoxon rank sum tests.

Eligibility Criteria

• Ages Eligible for Study: 25 Years to 85 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age: 25-85 years.
• Women with a history of invasive breast cancer, DCIS, or LCIS
• Creatine labs drawn within 90 days as part of Standard of Care.
• Bothersome hot flashes (defined by their occurrence of two or more hot flashes a day and/or of sufficient severity to prompt the patient to seek therapeutic intervention).
• Presence of hot flashes for >30 days prior to study entry.
• Ability to complete questionnaire(s) by themselves or with assistance.
• Ability to provide informed written consent.
• Life expectancy ≥6 months.
• Willing to work with the enrolling institution for follow-up (during the Active Monitoring Phase of the study).
• ECOG Performance Status (PS) = 0, 1.

Exclusion Criteria:

• Pregnancy (Assessed on Intake Questionnaire. Positive Answer exclusionary)
• Any of the following current (≤4 weeks prior) or planned therapies:
• Antineoplastic chemotherapy (anti-HER2 agents allowed)
• Androgens
• Estrogens (any delivery route)
• Progestogens
• Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period
• SSRIs/SNRIs
• Gabapentin
• Clonidine
• Oxybutinin
• Stage IV or V renal disease or GFR<30 in the last 90 days

Contacts and Locations

Locations

United States, Florida

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224

Sponsors and Collaborators

Mayo Clinic

Investigators

• Principal Investigator: Dawn M Mussallem; Mayo Clinic

  Study Documents (Full-Text)

Documents provided by Dawn M. Mussallem, D.O., Mayo Clinic:

Study Protocol  [PDF] April 10, 2018

More Information

Additional Information:

Mayo Clinic Clinical Trials 

• Responsible Party: Dawn M. Mussallem, D.O., Mayo Clinic
• ClinicalTrials.gov Identifier: NCT03564665
• Other Study ID Numbers: 18-000948
• First Posted: June 21, 2018
• Last Update Posted: April 12, 2021
• Last Verified: April 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Hot Flashes